Last reviewed 2026-04-19 · How we verify

Diabetes mellitus type 2

Approved treatments

• Zemiglo
• Suiny
• Suglat
• Glisepin
  Glisoxepide works by blocking potassium channels in the pancreas, allowing more insulin to be released.
• Dapaglifozin · MedImmune LLC
• Suganon · Dong-A ST
• Micronase · Sanofi
• Twymeeg · SUMITOMO DAINIPPON PHARMA Co., Ltd.
• Tradjenta · EMS
• Jardiance · Boehringer Ingelheim
  SYNJARDY combines empagliflozin, which inhibits SGLT2 to increase urinary glucose excretion, and metformin HCl, which improves glucose tolerance and insulin sensitivity.
• Trulicity · Eli Lilly
  Dulaglutide activates GLP-1 receptors, increasing insulin release and decreasing glucagon secretion and gastric emptying.
• Victoza · Novo Nordisk
• Amaryl · Sanofi
  Amaryl works by binding to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, closing the channel and depolarizing the pancreatic beta cell membrane, leading to insulin release.
• Precose · Bayer
• Mounjaro · Eli Lilly
  Tirzepatide is a dual GIP and GLP-1 receptor agonist with C20 fatty diacid for albumin binding.
• Lantus · Sanofi
  Lantus works by mimicking the action of natural insulin to lower blood sugar levels.
• Januvia · Zydus Lifesciences
  Januvia works by blocking an enzyme that breaks down hormones that help the body release insulin.
• Invokana · Johnson & Johnson
  Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption.
• Diabinese · Pfizer
• Burcol
  Burcol works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells.
• Dymelor · Eli Lilly
• Brenzavvy · Theracosbio
  Bexagliflozin inhibits SGLT2 to reduce renal glucose reabsorption and increase urinary glucose excretion.
• Glucophage · Generic (originally Merck Serono/Lipha)
  Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia.
• Jalra
• Tradjenta · Boehringer Ingelheim
  Tradjenta works by blocking an enzyme that breaks down hormones that help the body release insulin.
• Januvia · Johns Hopkins University
• duvie · Pusan National University Hospital
• Liraglutid · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Tradjenta · Boehringer Ingelheim
  Tradjenta works by blocking the DPP-4 enzyme, which normally breaks down incretin hormones that help regulate blood sugar levels.
• Actos · Takeda
• Saxenda · Seoul National University Hospital
• Victoza · Hanmi Pharmaceutical Company Limited
• Glucophage · Dr. Reddy's Laboratories Limited
• Glucotrol · Pfizer
  Glucotrol works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells.
• Lantus · Rijnstate Hospital
• MITIGLINIDE
• Apleway
• Diabyl
• Duvie · Chong Kun Dang
• Lyumjev · McGill University Health Centre/Research Institute of the McGill University Health Centre
• DAPA · Astrazeneca Ab
• Starlix · Novartis
  Starlix works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells.
• Gondafon
  Gondafon works by stimulating insulin release from the pancreas.
• Glustat
• Nesina · Takeda
  Nesina works by blocking an enzyme that breaks down incretin hormones, allowing more insulin to be released and less glucagon.
• Farxiga · AstraZeneca
  Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine.
• Humulin · Eli Lilly
  Humulin works by binding to insulin receptors on cells, triggering a cascade of signals that lower blood glucose levels.
• Steglatro · Merck & Co.
  Steglatro works by blocking the kidneys' ability to reabsorb glucose, allowing excess glucose to be excreted in the urine.
• Adlyxin · Sanofi-Aventis Us Llc
  Adlyxin works by mimicking the action of the GLP-1 hormone to help regulate blood sugar levels.
• Humalog · Eli Lilly
  Humalog works by mimicking the natural hormone insulin to help cells absorb glucose from the bloodstream.

Clinical guidelines

• FDA label — adj
  as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• FDA label — adj
  to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events
• FDA label — adj
  ZITUVIMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• FDA label — adj
  Empagliflozin, as a component of SYNJARDY or SYNJARDY XR, is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
• FDA label — adj
  Empagliflozin, as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of CV death and hospitalization for heart failure in adults with heart failure.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Diabetes mellitus type 2 patent landscape — cliff calendar, originator estates, attackable patents
• Diabetes mellitus type 2 treatment landscape brief
• Diabetes mellitus type 2 treatment updates RSS

Frequently asked questions about Diabetes mellitus type 2

Related

• Treatment landscape: Diabetes mellitus type 2 patent cliff · Diabetes mellitus type 2 CI report
• Treatment: Zemiglo
• Treatment: Suiny
• Treatment: Suglat
• Treatment: Glisepin
• Treatment: Dapaglifozin · MedImmune LLC
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing